Skip to content

Improving the health of patient with heart disease through intelligent remote ischemic conditioning: the i-RIC trial

Impact of intelligent “Internet Plus” based full disease cycle remote ischemic conditioning program (i-RIC) on clinical and functional outcomes in patients undergoing percutaneous coronary intervention: a pragmatic multicenter randomized controlled clinical trial

Status
Active, not recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2000031550
Enrollment
Unknown
Registered
2020-04-04
Start date
2020-07-01
Completion date
Unknown
Last updated
2020-04-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute myocardial infarction

Interventions

i-RIC group:PCI, Usual care, and i-RIC program (pre-, per- and post-operative RIC combined with “Internet Plus”-based long-term RIC).
Control group:PCI and Usual care

Sponsors

Department of Rehabilitation Medicine, the First Affiliated Hospital of Nanjing Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1) Newly developed STEMI according to clinical symptoms, ECG and laboratory confirmation; 2) Adult patients aged >18 yr; 3) Scheduled for PCI; 4) With normal cognitive function indicated by MMSE score >16 and able to cooperate with intervention; 5) Agreed to participate and signed the consent form.

Exclusion criteria

Exclusion criteria: 1) Previous STEMI or non-STEMI; 2) Previous CABG; 3) Previous stroke; 4) Developed thrombolysis within the last 30 days; 5) Cardiogenic shock history; 6) Persistent atrial fibrillation history; 7) Severe complications (e.g. ventricular septal rupture, free wall rupture or acute severe mitral regurgitation) warrant surgical interventions; 8) With peripheral neuropathy, peripheral artery disease, superficial thrombophlebitis or deep vein thrombosis; 9) Estimated survival period less than 12 months due to malignancies or severe systemic diseases; 10) Contraindicated through cardiac MRI; 11) Participated in other trials previously.

Design outcomes

Primary

MeasureTime frame
Major adverse cardiac and cerebrovascular events (MACCE);

Secondary

MeasureTime frame
All-cause mortality (ACM);Myocardial reinfarction rate;Readmission rate for heart failure;Ischemic stroke rate;Unplanned revascularization rate (URR);Plasma concentration of MI-related key biomarkers;Infarct size;Cardiac function;Cardiopulmonary endurance;Health-related quality of life (HRQoL);Total hospital length of stay;Total medical cost;Compliance;

Countries

China

Contacts

Public ContactLu Xiao

Department of Rehabilitation Medicine, the First Affiliated Hospital of Nanjing Medical University

luxiao1972@163.com+86 13813958023

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 26, 2026